

Gilead Sciences signs royalty-free licensing deals with three generic makers to support future Ebola antiviral access across 127 nations.
You can purchase shares of Gilead Sciences (NASDAQ:GILD) through any online brokerage.
Other companies in Gilead Sciences’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Moderna Inc (NASDAQ:MRNA).
Gilead Sciences has a consensus price target of $155.46.
The stock price for Gilead Sciences (NASDAQ: GILD) is $167.58 last updated November 20, 2026 at 7:53 PM EST.
There are no upcoming dividends for Gilead Sciences.
Gilead Sciences does not have any upcoming earnings scheduled.
There is no upcoming split for Gilead Sciences.
Gilead Sciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug...